Drug Trial Radar · NCT02258074
The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE
Last checked: Nov 20, 2026Latest source record: Aug 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
205
Actual
Start
Mar 2015
Primary completion
Nov 2018
Study completion Sep 2019
Sponsor
- Lead sponsor
- The Cleveland ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- First posted
- Oct 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The COMBINE clinical trial is a pilot study evaluating the effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor 23 (FGF23) in patients with Chronic Kidney Disease (CKD) stages 3-4.
Conditions
- Chronic Kidney Disease
Interventions
NicotinamideDrug
Lanthanum CarbonateDrug
Placebo (for Nicotinamide)Drug
Sugar pill manufactured to mimic Nicotinamide 750 mg capsule
Placebo (for lanthanum carbonate)Drug
Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- FGF23Time frame: Baseline to 12 months
- Serum Phosphate (mg/dl)Time frame: Baseline to 12 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of California at San Diego
San Diego, California
Denver Nephrology Research
Denver, Colorado
George Washington University
Washington D.C., District of Columbia
NorthShore University Health System
Chicago, Illinois
Northwestern University
Chicago, Illinois
University of Utah
Salt Lake City, Utah
Utah VA
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.